Acumen Pharmaceuticals, Inc. Common Stock
ABOSStock
$2.17+69.80%52W
Market Cap$160.35M
P/E—
Div yield—
Beta0.31
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)20.41%
Price vs S&P 500 (4W)8.52%
VGM Score60.23
Market Capitalization$160.35M
Earnings Surprise History
Q1 26-0.33est. -0.41
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.42
4.42
4.42
4.42
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ABOSAcumen Pharmaceuticals, Inc. Common Stock | — | — | B | $2.17 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing ACU193, a monoclonal antibody designed to treat Alzheimer's disease by targeting amyloid-beta oligomers. The company's therapeutic approach seeks to address what management identifies as a key underlying cause of neurodegeneration.